PATENT CLAIM ANALYSIS

Application Number: 15868688
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "001900"]

Abstract:
The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.

Claim (Index 20):
The method of  claim 19 , wherein the FGF-21 mimetic is selected from the group consisting of a protein having at least about 96% amino acid sequence identity to the amino acid sequence shown in SEQ ID NO: 1 and having FGF-21 activity, a FGF-21 fusion protein, and a FGF-21 conjugate.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 86.0
- Lexical Diversity: 1.42857
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15248712', '15851963', '13626207', '14630206', '14987338']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8057665145818156
- 35 USC 102 Novelty (BERT): 0.4934038773285955
- Combined Prediction Score: 0.7745302508564936
- Mean Citation Score: 249.016272
- Max Citation Score: 256.4285
- Similarity Product: 206.7581885735393

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test